会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 12. 发明申请
    • YKL-40 MONOCLONAL AUTHORITY
    • YKL-40单克隆抗体
    • US20090175870A1
    • 2009-07-09
    • US11817244
    • 2006-02-16
    • Richard BonnichsenPaul Price
    • Richard BonnichsenPaul Price
    • A61K39/395C07K16/18C07K5/00C07K7/00C12N5/06A61K38/08
    • C07K16/30A61K2039/505C07K2317/34C07K2317/73
    • The present invention relates to monoclonal anti-human YKL-antibodies which are capable to modulate biological processes in which YKL-40 plays a prominent role, e.g. inhibit the growth and/or inducing apoptosis of cells, in particular cancer cells. The invention also relates to pharmaceutical compositions comprising said antibodies and uses said antibodies and/or pharmaceutical compositions for treatment of a disease wherein inhibition of cell growth, cell differentiation, remodelling of extracellular matrix, metastasis and/or induction of cell death due to apoptosis is a prerequisite for successful curing. An antibody of the invention is capable of inhibiting biological function of YKL-40 in the above mentioned processes by binding to a specific epitope on YKL-40.
    • 本发明涉及能够调节其中YKL-40起突出作用的生物学过程的单克隆抗人YKL-抗体。 抑制细胞,特别是癌细胞的生长和/或诱导细胞凋亡。 本发明还涉及包含所述抗体的药物组合物,并且使用所述抗体和/或药物组合物来治疗疾病,其中抑制细胞生长,细胞分裂,细胞外基质的重塑,转移和/或由细胞凋亡引起的细胞死亡的诱导是 成功治愈的先决条件。 本发明的抗体能够通过与YKL-40上的特异性表位结合而在上述方法中抑制YKL-40的生物学功能。
    • 16. 发明授权
    • YKL-40 monoclonal antibody
    • YKL-40单克隆抗体
    • US08673301B2
    • 2014-03-18
    • US13290803
    • 2011-12-02
    • Richard BonnichsenPaul Price
    • Richard BonnichsenPaul Price
    • A61K39/395
    • C07K16/30A61K2039/505C07K2317/34C07K2317/73
    • The present invention relates to monoclonal anti-human YKL-antibodies which are capable to modulate biological processes in which YKL-40 plays a prominent role, e.g. inhibit the growth and/or inducing apoptosis of cells, in particular cancer cells. The invention also relates to pharmaceutical compositions comprising said antibodies and uses said antibodies and/or pharmaceutical compositions for treatment of a disease wherein inhibition of cell growth, cell differentiation, remodelling of extracellular matrix, metastasis and/or induction of cell death due to apoptosis is a prerequisite for successful curing. An antibody of the invention is capable of inhibiting biological function of YKL-40 in the above mentioned processes by binding to a specific epitope on YKL-40.
    • 本发明涉及能够调节其中YKL-40起突出作用的生物学过程的单克隆抗人YKL-抗体。 抑制细胞,特别是癌细胞的生长和/或诱导细胞凋亡。 本发明还涉及包含所述抗体的药物组合物,并且使用所述抗体和/或药物组合物来治疗疾病,其中抑制细胞生长,细胞分裂,细胞外基质的重塑,转移和/或由细胞凋亡引起的细胞死亡的诱导是 成功治愈的先决条件。 本发明的抗体能够通过与YKL-40上的特异性表位结合而在上述方法中抑制YKL-40的生物学功能。
    • 17. 发明申请
    • YKL-40 MONOCLONAL ANTIBODY
    • YKL-40单克隆抗体
    • US20120149882A1
    • 2012-06-14
    • US13290803
    • 2011-12-02
    • Richard BonnichsenPaul Price
    • Richard BonnichsenPaul Price
    • C07K16/40
    • C07K16/30A61K2039/505C07K2317/34C07K2317/73
    • The present invention relates to monoclonal anti-human YKL-antibodies which are capable to modulate biological processes in which YKL-40 plays a prominent role, e.g. inhibit the growth and/or inducing apoptosis of cells, in particular cancer cells. The invention also relates to pharmaceutical compositions comprising said antibodies and uses said antibodies and/or pharmaceutical compositions for treatment of a disease wherein inhibition of cell growth, cell differentiation, remodelling of extracellular matrix, metastasis and/or induction of cell death due to apoptosis is a prerequisite for successful curing. An antibody of the invention is capable of inhibiting biological function of YKL-40 in the above mentioned processes by binding to a specific epitope on YKL-40.
    • 本发明涉及能够调节其中YKL-40起突出作用的生物学过程的单克隆抗人YKL-抗体。 抑制细胞,特别是癌细胞的生长和/或诱导细胞凋亡。 本发明还涉及包含所述抗体的药物组合物,并且使用所述抗体和/或药物组合物来治疗疾病,其中抑制细胞生长,细胞分裂,细胞外基质的重塑,转移和/或由细胞凋亡引起的细胞死亡的诱导是 成功治愈的先决条件。 本发明的抗体能够通过与YKL-40上的特异性表位结合而在上述方法中抑制YKL-40的生物学功能。